Key result
Bemiparin reduced the percentage of subendothelial matrix covered by platelets to 5.40% compared to 15.70% in the control group.
Why the study?
Does low-molecular-weight heparin (bemiparin or dalteparin) reduce platelet-subendothelium interaction compared to unfractionated heparin in human blood under flow conditions?
Does low-molecular-weight heparin (bemiparin or dalteparin) reduce platelet-subendothelium interaction compared to unfractionated heparin in human blood under flow conditions?
In an in vitro human tissue model, the low-molecular-weight heparins bemiparin and dalteparin inhibited platelet-subendothelial interactions under flow conditions more effectively than unfractionated heparin.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for bemiparin in flow models; does not support clinical use or LMWH superiority over unfractionated heparin.
We compared the effects of the low-molecular-weight heparin (LMWH), bemiparin, and dalteparin with unfractionated heparin (UFH) on the platelet subendothelium interaction under flow conditions. All three compounds decreased the percentage of subendothelial matrix covered by platelets, although the effect of LMWH was greater than that of UFH. Subendothelial matrix covered with platelet structures greater than 100 square microns was significantly reduced by all three compounds; the effect of bemiparin tended to be greater than that of the other two heparins.
No takes yet. Share an insight, caveat, or question.
Correa et al. (2008) studied Healthy volunteers (n=5). Bemiparin vs. Control (trisodium citrate) was evaluated on Percentage of subendothelial matrix covered by platelets (p=<0.001). Bemiparin reduced the percentage of subendothelial matrix covered by platelets to 5.40% compared to 15.70% in the control group.
Synapse has enriched 10 related papers. Consider them for comparative context: